Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Amortization of Deferred Charges (2025)

Centessa Pharmaceuticals (CNTA) has disclosed Amortization of Deferred Charges for 1 consecutive years, with $279000.0 as the latest value for Q4 2025.

  • Quarterly Amortization of Deferred Charges changed N/A to $279000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $1.2 million for FY2025, N/A changed from the prior year.
  • Amortization of Deferred Charges for Q4 2025 was $279000.0 at Centessa Pharmaceuticals, up from $271000.0 in the prior quarter.
  • The five-year high for Amortization of Deferred Charges was $312000.0 in Q1 2025, with the low at $271000.0 in Q3 2025.